Investors

Investors

About Us - iTeos Overview

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immune-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

grid News

Latest press releases
  • iTeos to Present at Upcoming Investor Conferences in March

    Corporate
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    Corporate
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference

    Corporate
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference

    Corporate
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update

    Financial
    - Patient enrol l ment in Phase 1/2 stud ies of EOS-850 A 2A R antagonist and EOS-448 FCγ R-enabled anti-TIGIT antibody continue s with initial data expected in 1H21 -  - Strong cash position to support ongoing clinical development and operations into 2023 - CAMBRIDGE, Mass.
  • iTeos Appoints Matthew Roden, Ph.D. to Board of Directors

    Financial
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos to Participate in Upcoming Investor Conferences in November

    Financial
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos to Participate in Upcoming Investor Conferences in September

    Financial
    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 08, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
  • iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update

    Financial
    - July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 - - EOS-850 A 2A R antagonist and EOS-448 FC g R-enabled anti-TIGIT antibody continue to progress in clinical trials - CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept.